Ravindra Majeti

30.3k citations

161 papers · 16.4k indexed · 12 hit papers · h-index 55

Molecular Biology top 0.5%
Immunology top 0.1%
Hematology top 0.1%
Oncology top 0.5%
Cancer Research top 0.5%

Co-authors: Irving L. Weissman Mark P. Chao M. Ryan Corces Siddhartha Jaiswal Christopher Y. Park Ash A. Alizadeh Wendy W. Pang Nico van Rooijen
Topics: Acute Myeloid Leukemia Research (80 papers)Phagocytosis and Immune Regulation (32 papers)Cancer Genomics and Diagnostics (31 papers)
Cited by: Hematology Immunology Oncology
Journals: Nature Science Cell
Partner nations: United States India Australia

In The Last Decade

Ravindra Majeti

153 papers receiving 16.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

2009 1.3k citations Ravindra Majeti, Mark P. Chao et al. profile →
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

2009 1.2k citations Christopher Y. Park, Mark P. Chao et al. profile →
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

2010 845 citations Mark P. Chao, Ash A. Alizadeh et al. profile →
Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution

2016 656 citations M. Ryan Corces, Steven M. Chan et al. profile →
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells

2016 641 citations Daniel P. Dever, Andreas Reinisch et al. profile →
Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47

2010 594 citations Mark P. Chao, Rachel Weissman-Tsukamoto et al. profile →
Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia

2012 522 citations Max Jan, M. Ryan Corces et al. profile →
The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications

2012 509 citations Mark P. Chao, Irving L. Weissman et al. profile →
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

2014 494 citations M. Ryan Corces, Wan‐Jen Hong et al. Proceedings of the National Academy of Sciences profile →
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

2015 418 citations Steven M. Chan, Danièl Thomas et al. profile →
Integrated Single-Cell Analysis Maps the Continuous Regulatory Landscape of Human Hematopoietic Differentiation

2018 397 citations M. Ryan Corces, Ravindra Majeti et al. profile →
Targeting Cancer Stemness in the Clinic: From Hype to Hope

2018 367 citations Ravindra Majeti et al. profile →

Peers

Countries citing papers authored by Ravindra Majeti

Since Specialization

Citations

This map shows the geographic impact of Ravindra Majeti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ravindra Majeti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ravindra Majeti more than expected).

Fields of papers citing papers by Ravindra Majeti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ravindra Majeti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ravindra Majeti. The network helps show where Ravindra Majeti may publish in the future.

Co-authorship network of co-authors of Ravindra Majeti

This figure shows the co-authorship network connecting the top 25 collaborators of Ravindra Majeti. A scholar is included among the top collaborators of Ravindra Majeti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ravindra Majeti. Ravindra Majeti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Intra-Leukemic Interferon Signaling Suppresses Expansion and Mediates Chemoresistance in Human AML 2025 ·Blood Cancer Discovery ·Daiki Karigane,Amy C. Fan,Toshinobu Nishimura,Kensuke Kayamori,Yusuke Nakauchi,Thomas Köhnke,(unknown),Asiri Ediriwickrema,(unknown),Rozario Thomas,(unknown),Melissa Stafford,Fabian P. Suchy,Jonas L. Fowler,Mark P. Chao,Tian Yi Zhang,Kyle M. Loh,Hiromitsu Nakauchi,Ravindra Majeti	0
2	Human ASXL1-Mutant Hematopoiesis Is Driven by a Truncated Protein Associated with Aberrant Deubiquitination of H2AK119 2024 ·Blood Cancer Discovery ·Thomas Köhnke,(unknown),(unknown),Eric J. Gars,(unknown),Amy C. Fan,Ravindra Majeti	12
3	IDH1 -Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation 2023 ·Blood Cancer Discovery ·Niklas Landberg,Thomas Köhnke,Yang Feng,Yusuke Nakauchi,Amy C. Fan,Miles H. Linde,Daiki Karigane,Kelly Lim,Rahul Sinha,Luca Malcovati,Danièl Thomas,Ravindra Majeti	9
4	Gene Correction of DNMT3A:R882H in Primary Human AML Demonstrates That This Mutation Is Not Required for Disease Maintenance, but Is Associated with Increased Leukemia Stem Cell Frequency 2023 ·Blood ·(unknown),Daiki Karigane,(unknown),Kensuke Kayamori,Amy C. Fan,Cailin Collins,Fabian P. Suchy,(unknown),Yang Feng,Yusuke Nakauchi,Eduardo Martínez‐Montes,Michael A. Koldobskiy,Andrew P. Feinberg,Ravindra Majeti	0
5	MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint 2023 ·Proceedings of the National Academy of Sciences ·Benjamin Smith,Anja Deutzmann,(unknown),(unknown),Renumathy Dhanasekaran,Christopher G. Dove,Delaney K. Sullivan,Simon Wisnovsky,Jessica C. Stark,John V. Pluvinage,Srividya Swaminathan,Nicholas M. Riley,Anand Rajan,Ravindra Majeti,Dean W. Felsher,Carolyn R. Bertozzi	40
6	Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy 2023 ·Cancer Discovery ·Miles H. Linde,Amy C. Fan,Thomas Köhnke,Aaron C. Trotman-Grant,(unknown),(unknown),(unknown),Naomi L. Haddock,(unknown),Eric J. Gars,Melissa Stafford,Payton L. Marshall,Christopher G. Dove,Ian L. Linde,Niklas Landberg,(unknown),Robbie G. Majzner,Tian Yi Zhang,Ravindra Majeti	33
7	TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions 2022 ·Cancer Discovery ·Naval Daver,Abhishek Maiti,Tapan M. Kadia,Paresh Vyas,Ravindra Majeti,Andrew H. Wei,Guillermo Garcia‐Manero,Charles Craddock,David A. Sallman,Hagop M. Kantarjian	83
8	Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability 2022 ·Cancer Discovery ·Danièl Thomas,Manhong Wu,Yusuke Nakauchi,Ming Zheng,(unknown),Kelly Lim,Niklas Landberg,Thomas Köhnke,Nirmal Robinson,(unknown),Monika Kutyna,Melissa Stafford,Devendra Hiwase,Andreas Reinisch,Gary Peltz,Ravindra Majeti	39
9	Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia 2021 ·Blood Cancer Discovery ·Kyle A. Romine,Tamilla Nechiporuk,Daniel Bottomly,Sophia Jeng,Shannon K. McWeeney,Andy Kaempf,M. Ryan Corces,Ravindra Majeti,Jeffrey Tyner	22
10	NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity 2021 ·Blood Cancer Discovery ·Rebecca M. Richards,Feifei Zhao,Katherine A. Freitas,Kevin R. Parker,Peng Xu,Amy C. Fan,Elena Sotillo,Mads Daugaard,Htoo Zarni Oo,Jie Liu,Wan‐Jen Hong,Poul H. Sorensen,Howard Y. Chang,Ansuman T. Satpathy,Robbie G. Majzner,Ravindra Majeti,Crystal L. Mackall	65
11	The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells 2021 ·Nature Communications ·Rajiv P. Sharma,Daniel P. Dever,Ciaran M. Lee,Armon Azizi,(unknown),Joab Camarena,Thomas Köhnke,Gang Bao,Matthew H. Porteus,Ravindra Majeti	21
12	Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience 2020 ·Leukemia & lymphoma ·Armon Azizi,Asiri Ediriwickrema,(unknown),Shyam A. Patel,William Shomali,Bruno C. Medeiros,David Iberri,Jason Gotlib,Gabriel N. Mannis,Peter L. Greenberg,Ravindra Majeti,Tian Yi Zhang	18
13	A Dysregulated DNA Methylation Landscape Linked to Gene Expression in MLL-Rearranged AML 2020 ·Epigenetics ·Michael A. Koldobskiy,Jordi Abante,Garrett Jenkinson,Elisabet Pujadas,(unknown),Feifei Zhao,Rakel Tryggvadóttir,Adrian Idrizi,Andreas Reinisch,Ravindra Majeti,John Goutsias,Andrew P. Feinberg	12
14	Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment 2018 ·Blood ·Haijiao Zhang,Beth Wilmot,Daniel Bottomly,Stephen E. Kurtz,Christopher A. Eide,Alisa Damnernsawad,Kyle A. Romine,Shyam A. Patel,Brian Druker,(unknown),Ravindra Majeti,Jeffrey Tyner	23
15	Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist 2017 ·Cancer Discovery ·Michael R. McKeown,M. Ryan Corces,Matthew L. Eaton,Chris Fiore,(unknown),(unknown),Mei Wei Chen,(unknown),Steven M. Chan,Julie L. Koenig,Kathryn Austgen,Matthew G. Guenther,David A. Orlando,Jakob Lovén,Christian Fritz,Ravindra Majeti	89
16	Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells 2017 ·Nature Immunology ·Dimitris Karamitros,Bilyana Stoilova,(unknown),Fiona Hamey,Andreas Reinisch,(unknown),Lynn Quek,Georg Otto,Emmanouela Repapi,Jessica Doondeea,Batchimeg Usukhbayar,Julien Calvo,Stephen Taylor,Nicolas Goardon,Emmanuelle Six,Françoise Pflumio,Catherine Porcher,Ravindra Majeti,Berthold Göttgens,Paresh Vyas	144
17	ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia 2016 ·Cancer Discovery ·Li Zhu,Qin Li,Stephen H.K. Wong,Min Huang,Brianna J. Klein,(unknown),(unknown),Masayuki Onishi,Dominik Schneidawind,Corina Buechele,Loren Hansen,Jesús Duque‐Afonso,Fangfang Zhu,Glòria Mas Martín,Or Gozani,Ravindra Majeti,Tatiana G. Kutateladze,Michael L. Cleary	112
18	SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells 2016 ·Clinical Cancer Research ·Emily Piccione,Silvia Juárez,Serena Tseng,Jie Liu,Melissa Stafford,Cyndhavi Narayanan,Lijuan Wang,Kipp Weiskopf,Ravindra Majeti	41
19	Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages 2015 ·Proceedings of the National Academy of Sciences ·James Scott McClellan,Christopher G. Dove,Andrew J. Gentles,Christine E. Ryan,Ravindra Majeti	44
20	Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia 2010 ·Cancer Research ·Mark P. Chao,Ash A. Alizadeh,Chad Tang,Max Jan,Rachel Weissman-Tsukamoto,Feifei Zhao,Christopher Y. Park,Irving L. Weissman,Ravindra Majeti	294

About Ravindra Majeti

Ravindra Majeti is a scholar working on Hematology, Immunology and Cancer Research, having authored 161 papers that have together received 16.4k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (80 papers), Phagocytosis and Immune Regulation (32 papers) and Cancer Genomics and Diagnostics (31 papers). The work is most often cited by research in Hematology (4.7k citations), Immunology (7.4k citations) and Oncology (3.9k citations). Ravindra Majeti has collaborated with scholars based in United States, India and Australia. Frequent co-authors include Irving L. Weissman, Mark P. Chao, M. Ryan Corces, Siddhartha Jaiswal, Christopher Y. Park, Ash A. Alizadeh, Wendy W. Pang, Nico van Rooijen, Danièl Thomas and Arthur Weiss. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact